veyora bpc 157 BPC-157: A Prohibited Peptide and an Unapproved Drug Found in Health and Wellness Products BPC-157 - Vitality Research

Tendinopathy requires the full 4 to 8 week protocol for meaningful resolution

GHRH Peptides Side-by-Side Feature Receptor Target Tesamorelin GHRH receptor Sermorelin GHRH receptor CJC-1295 (DAC) GHRH receptor Feature Peptide Length Tesamorelin 44 amino acids (modified) Sermorelin 29 amino acids CJC-1295 (DAC) 29 amino acids + DAC Feature Half-Life Tesamorelin 26-38 minutes Sermorelin 11-12 minutes CJC-1295 (DAC) ~6-8 days Feature Dosing Frequency Tesamorelin Once daily Sermorelin Once nightly CJC-1295 (DAC) 1-2x weekly Feature FDA Status Tesamorelin Approved (2010

Monitor patients for 30 minutes after infusion and ensure emergency treatment (e.g epinephrine) is available

We also run our 80+ biomarker panel to check for the downstream damage SIBO causes: iron, B12, folate, vitamin D, inflammatory markers, thyroid function, and a full metabolic workup